Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Goncharov, Sergey V
As diabetes is a major risk factor for CKD [67], specialized expert groups such as the Kidney Disease: Improving Global Outcomes (KDIGO) team, with the endorsement of both ADA and EASD, recommend that glycemic management for T2D patients with CKD should involve a combination of metformin and a SGLT-2 inhibitor as first-line therapy, with other drugs such as SUs considered only when additional therapies are needed for optimum glycemic control [68]
are diabetic and another 96 million prediabetic
Activation of GLP-1 Receptor Enhances the Chemosensitivity of Pancreatic Cancer Cells
US$ 24.49
US$ 20.58
US$ 23.02
US$ 24.67
US$ 25.35
US$ 23.34
US$ 29.67
